drugset

drugset / Trial / NCT04398953

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

NCT04398953 ↗

Phase 2 Unknown 102 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).

Timeline

Start: 2020-07-20
Primary completion: 2021-09
Completion: 2021-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQ-B3525	Small molecule	20 mg	Oral

Indications